Search Results

You are looking at 101 - 110 of 150 items for :

  • "renal cell carcinoma" x
Clear All
Full access

Ravi A. Madan, Thomas Schwaab and James L. Gulley

( Suppl 2 ): 14639 – 14645 . 2 Schwaab T Ernstoff MS . Therapeutic vaccines in renal cell carcinoma . Therapy 2011 ; 4 : 369 – 377 . 3 So-Rosillo R Small EJ . Sipuleucel-T (APC8015) for prostate cancer . Expert Rev Anticancer

Full access

Kamel Izeradjene and Sunil R. Hingorani

dendritic cells on renal cell carcinoma . Anticancer Res 2002 ; 22 : 4281 – 4284 . 107. Dirkx AE Oude Egbrink MG Wagstaff J Griffioen AW . Monocyte/macrophage infiltration in tumors: modulators of angiogenesis . J Leukoc Biol 2006 ; 80

Full access

Carlos Camps, Joan Albanell, Antonio Antón, Enrique Aranda, Alfredo Carrato, Javier Cassinello, Daniel Castellano, Juan J. Cruz, Pilar Garrido, Vicente Guillem, Cristina Grávalos, Guillermo López, César Llorente, Antonio Lorenzo, Ana Lluch, Emilio Ignacio and Eduardo Díaz-Rubio

systematic review . Ann Surg Oncol 2013 ; 20 : 381 – 398 . 21. Wood L Bjarnason GA Black PC . Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma . J Oncol Pract 2013

Full access

Michael Cecchini, Jeffrey Sklar and Jill Lacy

rare, but have been described in cancers of the pancreas, head and neck, esophagus, biliary tract, prostate, colon, and ovaries, as well as in sarcomas and papillary renal cell carcinoma. 12 – 18 Mutations in EGFR are present in rare cases of

Full access

Lillie D. Shockney

small percentage of patients with certain cancers (eg, colon cancer, renal cell carcinoma, some sarcomas) that recur distantly with oligometastatic disease may be able to undergo surgery for a possible cure. 11 , 12 In many clinical situations, however

Full access

Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky and Karen L. Reckamp

without acquired resistance in the lung. The evolution of the patient’s lung tumor histology from adenocarcinoma to squamous cell carcinoma is also of interest. Tumor heterogeneity leading to cancer evolution is a complex process, as shown in renal cell

Full access

Nikhil Khandelwal, Ian Duncan, Tamim Ahmed, Elan Rubinstein and Cheryl Pegus

Web site . Available at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcmanual_v4_10-4-99.pdf . Assessed May 20, 2011 . 15 Eisen T Oudard S Gravis G . Sorafenib for older patients with renal cell carcinoma

Full access

Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan and Steven Brem

dose only offered an improvement in median time to progression but not response rate or overall survival. 12 In metastatic renal cell carcinoma, no difference was seen between bevacizumab doses of 3 and 10 mg/kg with respect to response rate, time to

Full access

Saroj Niraula and Zoann Nugent

trials with OS as the primary or coprimary end point. The remaining studies included PFS, event-free survival, or response rates as the primary end point. Interestingly, 3 drugs—pazopanib for renal cell carcinoma and ceritinib and crizotinib for non

Full access

Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold and May T. Cho

impairment was due to cirrhosis from alcohol ingestion or hepatitis and metastatic disease. Primary neoplasms in these patients included Hodgkin lymphoma, 29 melanoma, renal cell carcinoma, small cell and non–small lung cancers, and urothelial carcinoma, 28